a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10624177				
	Filing Date		2003-07-22				
First Named Inventor J.R. I		J.R. I	IRELAND et al.				
	Art Unit		3763				
	Examiner Name	Laura	ura A. Bouchelle				
	Attorney Docket Numb	er	0059-1023				

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3631847		1972-01-04	Hobbs II	
	2	4270532		1981-06-02	Franctzki et al.	
	3	4282872		1981-08-11	Francizki et al.	
	4	4373527		1983-02-15	Fischell	
	5	4392849		1983-07-12	Petre et al.	
	6	4395259		1983-07-26	Prestole et al.	
	7	4433072		1984-02-21	Pusineri et al.	
	8	4443218		1984-04-17	DeCant, Jr. et al.	

	Application Number		10624177	
NEODIA TION DIOCI COURT	Filing Date		2003-07-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	J.R. I	RELAND et al	
Not for submission under 37 CFR 1.99)	Art Unit		3763	
Not for Submission under or or it is a	Examiner Name	Laura	a A. Bouchelle	
	Attorney Docket Numb	er	0059-1023	

9	4469481	1984-09-04	Kobayashi	
10	4475901	1984-10-09	Kraegen et al.	
11	4494950	1985-01-22	Fischell	
12	4529401	1985-07-16	Leslie et al.	
13	4542532	1985-09-17	McQuilkin	
14	4550731	1985-11-05	Batina et al.	
15	4559037	1985-12-17	Franetzki et al.	
16	4562751	1986-01-07	Nason et al.	
17	4671288	1987-06-09	Gough	
18	4678408	1987-07-07	Nason et al.	
19	4685903	1987-08-11	Cable et al.	

	Attorney Docket Numb	_	a A. Bouchelle 0059-1023			
( Not for submission under 37 CFR 1.99)	Art Unit	_	3763			
STATEMENT BY APPLICANT	First Named Inventor	J.R.	RELAND et al			
INFORMATION DISCLOSURE	Filing Date		2003-07-22			
	Application Number		10624177			

20	4696671	1987-09-29	Epstein et al.	
21	4703756	1987-11-03	Gough et al.	
22	4731051	1988-03-15	Fischell	
23	4731726	1988-03-15	Allen, III	
24	4781798	1988-11-01	Gough	
25	4803625	1989-02-07	Fu et al.	
26	4809697	1989-03-07	Causey III et al.	
27	4826810	1989-05-02	Aoki	
28	4871351	1989-10-03	Feingold	
29	4898578	1990-02-06	Rubalcaba Jr.	
30	4935105	1990-06-19	Churchouse	

	Application Number		10624177	
	Filing Date		2003-07-22	
INFORMATION DISCLOSURE	First Named Inventor J.R. I		IRELAND et al	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		3763	
(Not for Submission under or or it issue	Examiner Name Laur		A. Bouchelle	
	Attorney Docket Numb	er	0059-1023	

31	4953552	1990-09-04	DeMarzo	
32	5019974	1991-05-28	Beckers	
33	5034004	1991-07-23	Crankshaw	
34	5050612	1991-09-24	Matsumura	
35	5078683	1992-01-07	Sancoff et al.	
36	5080653	1992-01-14	Voss et al.	
37	5097122	1992-03-17	Colman et al.	
38	5100380	1992-03-31	Epstein et al.	
39	5101814	1992-04-07	Palti	
40	5108819	1992-04-28	Heller et al.	
41	5113869	1992-05-19	Napphoiz et al.	

43	5165407		1992-11-24	Wilson et al.			
44	5211626		1993-05-18	Frank et al.			
45	5216597		1993-06-01	Beckers			
46	5262035		1993-11-16	Gregg et al.			
47	5262305		1993-11-16	Heller et al.			
48	5264104		1993-11-23	Gregg et al.			
49	5264105		1993-11-23	Gregg et al.			
50	5266013		1993-11-30	Aubert et al.			
to ad	d additional U.S. Paten					Add	
		U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Cite No	Publication Number			Name of Patentee or Applicant of cited Document	Releva	nt Passag	
	444 45 46 47 48 49	44 5211626 45 5216397 46 5262035 47 5262305 48 5264104 49 5264105 50 5266013 to add addistanal U.S. Paten	44 5211626 45 5216697 46 5262035 47 5262305 48 5264104 49 5264105 50 5266013 to add additional U.S. Patent citation	44 5211626 1993-05-19 45 5216597 1993-06-01 46 5262035 1993-11-16 47 5262305 1993-11-16 48 5264104 1993-11-23 49 5264105 1993-11-23 50 5269013 1993-11-30 50 3269013 1993-11-30 510 add additional U.S. Patent citation information pi	1993-05-18 Frank et al.  1993-05-18 Frank et al.  1993-05-18 Frank et al.  1993-05-01 Beckers  1993-11-16 Gragg et al.  1993-11-16 Hetter et al.  1993-11-23 Gragg et al.  1993-11-20 Gragg et al.	1993-05-18   Frank et al.	44 5211626 1993-05-19 Frank et al. 45 5216597 1993-06-01 Beckers 46 5262035 1993-11-16 Gregg et al. 47 5262305 1993-11-16 Heller et al. 48 5264104 1993-11-23 Gregg et al. 49 5264105 1993-11-23 Gregg et al. 49 5264105 1993-11-23 Gregg et al. 40 5264105 1993-11-20 Regg et al. 40 5264105 1993-11-20 Regg et al. 41 5264105 1993-11-23 Regg et al. 42 5264105 1993-11-23 Regg et al. 43 5264105 1993-11-23 Regg et al. 44 5264105 1993-11-23 Regg et al. 45 5264105 1993-11-23 Regg et al. 46 5266103 Regg et al. 47 5262005 Regg et al. 48 5264105 1993-11-20 Regg et al. 49 5264105 Regg et al.

| Application Number | 19024177 | Filing Date | 2003-07-22 |
| STATEMENT BY APPLICANT | Filing Date | 2003-07-22 |
| Filing Date | 2

	1								
If you wisi	h to a	l dd additional U.S. Publ							
			FORE	GN PAT	TENT DOCUM	ENTS	Remov	e	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	where R	s or Relevant	
	1	4329229	DE		1995-03-09				
	2	0098592	EP		1984-01-18				
	3	0680727	EP		1995-11-08				
	4	0806738	EP		1997-11-12				
	5	0880936	EP		1998-12-02				
	6	1048264	EP		2000-11-02				
	7	1338295	EP EP		2003-08-27				
	8	2218831	GB		1989-11-22				П

					Applic	ation N	lumber		10624177 2003-07-22		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Art Unit			IRELAND et al			
( Not for submission under 37 CFR 1.99)			3763								
					Examiner Name Laura			a A. Bouchelle			
					Attorn	Attorney Docket Number			0059-1023		
		9	9528878	wo			1995-11-6	12			Ī

9	9528878	wo	1995-11-02		
10	9620745	wo	1996-07-11		
11	9636389	wo	1996-11-21		
12	9637246	wo	1996-11-28		
13	9721456	wo	1997-06-19		
14	9728736	wo	1997-08-14		
15	9800056	wo	1998-01-08		
16	9820439	wo	1998-05-14		
17	9824358	wo	1998-06-11		
18	9842407	wo	1998-10-01		
19	9849659	wo	1998-11-05		

				Applic	ation N	umber		10624177 2003-07-22		_
		TION DISCLOS NT BY APPLIC		The Trainer Internal			J.R.	R. IRELAND et al		
( Not for	( Not for submission under 37 CFR 1.99)			Art Unit  Examiner Name Laura			a A. Boudhelle			
				Attorn	ey Doc	ket Numb	er	0059-1023		
	20	9856293	wo			1998-12-1	7			

20	9856293	wo	1998-12-17		
21	9859487	wo	1998-12-30		
22	9908183	wo	1999-02-18		
23	9910801	wo	1999-03-04		
24	9918532	wo	1999-04-15		
25	9922236	wo	1999-05-06		
26	9945375	wo	1999-09-10		
27	9945387	wo	1999-09-10		
28	9956613	wo	1999-11-11		
29	0019887	wo	2000-04-13		
30	0047109	wo	2000-08-17		

	31	0078210	wo		2000-12-28			
	32	0128416	wo		2001-04-26			
	33	0128495	wo		2001-04-26			
	34	0139089	wo		2001-05-31			
	35	0152718	wo		2001-07-26			
	36	0152727	wo		2001-07-26			
	37	0156454	wo		2001-08-09			
	38	0258537	wo		2002-08-01			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add	
	NON-PATENT LITERATURE DOCUMENTS Remove							
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when approp date, pages(s), volume-is		Τs
1	l l							

ABEL, P. et al., "Experience with an Implantable Glucose Sensor as a Prerequisite of an Artificial Beta Cell", Biomed.

Biochim., 1984, Acta 43, 5, pp. 577-584.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10624177			
	Filing Date		2003-07-22			
First Named Inventor J.R. I		J.R. I	IRELAND et al			
	Art Unit		3763			
Examiner Name Laura		Laura	A. Bouchelle			
	Attorney Docket Numb	er	0059-1023			

2	BODE, B.W. et al, "Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes", Diabetes Care, Vol. 19, No. 4, 1996, 324-327.	
3	BOLAND, E., "Teens Pumping it Up1 Insulin Pump Therapy Guide for Adolescents", 2nd Edition, 1999, 60 pp.	
4	BRACKENRIDGE, B.P., "Carbohydrate Gram Counting: A Key to Accurate Mealtime Boluses in Intensive Diabeles Therapy", Practical Diabelology, Vol. 11, No. 2, 1992, pp. 22–28.	
5	BRACKENRIDGE, B.P. et al., "Counting Carbohydrates: How to Zero in on Good Control using the MiniMed insulin Pump", MiniMed Technologies Inc., 1995, 26 pp.	
6	FARKAS-HRSCH, R. et al., "Continuous Subcutaneous Insulin Influsor: A Review of the Past and Its Implementation for the Future", Diabetes Spectrum From Research to Practice, Vol. 7, No. 2, 1994, pp. 80-84 and 136-138.	
7	HIRSCH, I.B. et al., "Intensive Insulin Therapy for Treatment of Type I Diabetes", Diabetes Care, Vol. 13, No. 12, 1990, pp. 1265-1283.	
8	KAWAMORI, R. et al., "Perfect Normalization of Excessive Glucagon Responses to Intravenous Argnine in Human Diabetes Melitus with the Artificial Beta-Cell", Rapid Publication from Diabetes, Vol. 29, September 1980, pp. 762-765.	
9	KULKARNI, K. et al., "Carbohydrate Counting: A Primer for Insulin Pump Users to Zero in on Good Control", MiniMed Inc., 1999, pp. 1-50.	
10	MARCUS, A.O. et al., "Insulin Pump Therapy: Acceptable Alternative to Injection Therapy", Postgraduate Medicine, Vol. 99, No. 3, 1996, pp. 125-143.	
11	MASTROTOTARO, J.J. et al., "An Electroenzymatic Sensor Capabble of 72 Hour Continuous Mentoring of Subcutaneous Glucose", Presentation given at the 14th International Diabetes Federation Congress in Washington, D.C., June 1991, 19 pp.	
12	MCKEAN, B., et al., "A Telemetry-instrumentation System for Chronically Implanted Glucose and Oxygen Sensors", IEEE Transactions on Biomedical Engineering, Vol. 35, No. 7, July 1988, pp. 526-532.	

Application Number 10624177
Filing Date 12030-722
Filing Date 1203

13	MINIMED, INC., "MiniMed 508 Insulin Pump Flipchart Guide to Insulin Pump Therapy", December 1999, 35 pp.	
14	MINIMED, INC., "MiniMed 508 Insulin Pump User's Guide", September 2001, pp. 1-145.	
15	MINIMED, INC., "MiniMed Dosage Catculator", 1994, 4 pp.	
16	MINIMED, INC., "Now I Carr: Correction Bolus Calculator and Meal Bolus Calculator", July 2000, 2 pp.	
17	MINIMED, INC., "Medizonic MiniMed Meal Bolus Calculator and Correction Bolus Calculator", International Version, February 2002, 4 pp.	
18	MINIMED, INC., "Now I Cart MiniMed Pump Therapy Brochure", September 2000, 10 pp.	
19	MINIMED, INC., "Now I Cars MiniMed Diabetes Management Packer", September 2000, 46 pp.	
20	MINIMED, INC., "Paradigm Infusion Pump: Model MMT-511 User Guide", January 2002, 83 pp.	
21	MONROE, D. et al., "Novel implantable glucose sensors", ACL, December 1989, pp. 8-16.	
22	NISHIDA, K. et al., "Clinical applications of the wearable artificial endocrine pancreas with the newly designed needle- type glucose sensor", Elsevier Science B.V., 1994, pp. 353-358.	
23	REED, J. "Living with Diabetes", Voice of the Diabetic, Vol. 11, No. 3, 1996, pp. 1-38.	

24	S-HCHRI, M. et al., "A Needie-Type Glacose Sensor — A Valuable Tool Not Chry for a Self-Blood Glucose Montoring But for a Viewande Artificial Panceraus-", Life Support Systems, Proceedings XI Annual Meeting ESAC, September 1984, Vol. 2, Supplement 1, pp. 7-9.	
25	SHICHIRI, M. et al., "An Artificial Endocrine Pancreas – Problems Awalting Solution for Long-Term Clinical Applications of a Glucose Sensor", Frontiers Med. Biol. Engng, VSP, Vol. 3, No. 4, 1991, pp. 283-292.	
26	SHICHIRI, M. et al., "Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas Variations in Daily Insulin Requirements to Glycemic Response", Rapid Publication from Diabetiss, Vol. 33, December 1994, pp.	
27	SHICHIRI, M. et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas", Diabetologia 24, 1983, pp. 179-184.	
28	SHICHIRI, M. et al., "Normalization of the Paradoxic Secretion of Glucagon in Diabetics Who Were Controlled by the Artificial Beta Cell", Diabetiss, Vol., 28, April 1979, pp. 272-275.	
29	SHICHIRI, M. et al., "Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Bood Glucose Monitoring in Diabetic Individuals", Diabetes Care, Vol. 9, No. 3, May-June 1996, pp. 299-301.	
30	SHICHIRI, M. et al., "The Wearable Artificial Endocrine Pancreas with a Needle-Type Gitucose Sensor: Perfect Gycemic Control in Ambulatory Diabetics", Acta Paedlett Jpn 26, 1984, pp. 359-370.	
31	SHICHIRI, M. et al., "Wearable Artificial Endocrine Plancress with Needle-Type Glucose Sensor", The Lancet, November 20, 1992, pp. 1129-1131.	
32	SHULTS, M.C. et al., "A Telemetry-instrumentation System for Monitoring Multiple Subcutaneously Implanted Clucose Sensors", IEEE Transactions on Biomedical Engineering, Vol. 41, No. 10, 1994, pp. 937-942.	
33	SKYLER, J.S., "Continuous Subculaneous Insulin Infusion [CSII] With Edernal Devices: Current Status", Update in Drug Delivery Systems, Futura Publishing Company, Chapter 13, 1989, pp. 163-183.	
34	STROWIG, S.M., "Initiation and Management of Insulin Pump Therapy", The Diabetes Educator, Vol. 19, No. 1, 1993, pp. 50-50.	

	EXAMINER SIGNATURE	
If you wish to	add additional non-patent literature document citation information please click the Add button Add	_
38	BANKS, P. (Ed.), "Insulin Infusion Pump Therapy", Intensive Diabetes Management, 1995, pp. 66-76.	
37	FREDRICKSON, L. (Ed.), "The Insulin Pump Therapy Book: Insights from the Experts", MiniMed Technologies, 1995, 172 pp.	
36	WANG, J. et al., "Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin", Analytical Chemistry, Vol. 73, No. 4, February 15, 2001, pp. 844-847.	
35	WALSH, J. et al., "Pumping Insulm: The Art of Using an Insulin Pump", MiniMed Technologies, 1989, 149 pp.	

Examiner Signature Date Considered Date Consid

1 See Kint Codes of USPTO Planto Documents at year, USPTO, DOLY or MPEP 901.04. \* Enter office and sessed the document, by the to-elect code (WIPO Standard ST.3.). \*\*Refreshapese plant documents, the reduction to the year of the eight or the Engerer many reported the senial number of the plant document. \*\*If American Standard ST.3.0 \*\*Refreshapese planto senior and senior senio

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10624177
Filing Date		2003-07-22
First Named Inventor J.R. I		RELAND et al
Art Unit		3763
Examiner Name	Laura	A. Bouchelle
Attorney Docket Number		0059-1023

## CERTIFICATION STATEMENT

Please see	37.0	CFR 1	97	and :	1 98	to make	the	appropriate	selection(s)	

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 178(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c) for the filing of the information disclosure statement. See 37 CFR 179(c) for the filing of the information disclosure statement. See 37 CFR 179(c) for the filing of the information disclosure statement. See 37 CFR 179(c) for the filing of the information disclosure statement. See 37 CFR 179(c) for the filing of the information disclosure statement was considered to the filing of the information disclosure statement was considered to the filing of the information of the filing of the information disclosure statement. See 37 CFR 179(c) for the filing of the information disclosure statement was considered to the filing of the information disclosure statement.

_	See attached certification statement	

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

.7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William Konrad/	Date (YYYY-MM-DD)	2006-09-05
Name/Print	William K. Konrad	Registration Number	28,868

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GAD 47 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be closed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552e(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the agriculation pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public insepciones or an issuand patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.